Jeremy R Chapman
Jeremy R Chapman
Clinical Professor, Sydney University, Westmead Hospital
Verified email at
TitleCited byYear
The natural history of chronic allograft nephropathy
BJ Nankivell, RJ Borrows, CLS Fung, PJ O'Connell, RDM Allen, ...
New England Journal of Medicine 349 (24), 2326-2333, 2003
Playing the end game: DNA double-strand break repair pathway choice
JR Chapman, MRG Taylor, SJ Boulton
Molecular cell 47 (4), 497-510, 2012
Cancer incidence before and after kidney transplantation
CM Vajdic, SP McDonald, MRE McCredie, MT Van Leeuwen, JH Stewart, ...
Jama 296 (23), 2823-2831, 2006
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation
BD Tait, C Süsal, HM Gebel, PW Nickerson, AA Zachary, FHJ Claas, ...
Transplantation 95 (1), 19-47, 2013
Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data
AC Webster, RC Woodroffe, RS Taylor, JR Chapman, JC Craig
Bmj 331 (7520), 810, 2005
Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology
BJ Nankivell, RJ Borrows, CLS Fung, PJ O'Connell, JR Chapman, ...
Transplantation 78 (4), 557-565, 2004
Chronic renal allograft dysfunction
JR Chapman, PJ O’Connell, BJ Nankivell
Journal of the American Society of Nephrology 16 (10), 3015-3026, 2005
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary
BL Kasiske, MG Zeier, JR Chapman, JC Craig, H Ekberg, CA Garvey, ...
Kidney international 77 (4), 299-311, 2010
RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection
JR Chapman, P Barral, JB Vannier, V Borel, M Steger, A Tomas-Loba, ...
Molecular cell 49 (5), 858-871, 2013
Chronic allograft nephropathy: current concepts and future directions
BJ Nankivell, JR Chapman
Transplantation 81 (5), 643-654, 2006
A quantitative review of heterozygosity–fitness correlations in animal populations
JR Chapman, S Nakagawa, DW Coltman, J Slate, BC Sheldon
Molecular ecology 18 (13), 2746-2765, 2009
Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials
AC Webster, VWS Lee, JR Chapman, JC Craig
Transplantation 81 (9), 1234-1248, 2006
Predicting glomerular filtration rate after kidney transplantation.
BJ Nankivell, SM Gruenewald, RD Allen, JR Chapman
Transplantation 59 (12), 1683-1689, 1995
Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease.
RM Bernstein, SH Morgan, J Chapman, CC Bunn, MB Mathews, ...
Br Med J (Clin Res Ed) 289 (6438), 151-152, 1984
Effect of histological damage on long-term kidney transplant outcome
BJ Nankivell, CA Fenton-Lee, DRJ Kuypers, E Cheung, RDM Allen, ...
Transplantation 71 (4), 515-523, 2001
Natural history, risk factors, and impact of subclinical rejection in kidney transplantation
BJ Nankivell, RJ Borrows, CLS Fung, PJ O’Connell, RDM Allen, ...
Transplantation 78 (2), 242-249, 2004
Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation
R Oberbauer, G Segoloni, JM Campistol, H Kreis, A Mota, J Lawen, ...
Transplant International 18 (1), 22-28, 2005
Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15 183 recipients
AC Webster, JC Craig, JM Simpson, MP Jones, JR Chapman
American Journal of Transplantation 7 (9), 2140-2151, 2007
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
G Xu, JR Chapman, I Brandsma, J Yuan, M Mistrik, P Bouwman, ...
Nature 521 (7553), 541, 2015
The global role of kidney transplantation
GG Garcia, P Harden, J Chapman
Kidney and Blood Pressure Research 35 (5), 299-304, 2012
The system can't perform the operation now. Try again later.
Articles 1–20